• Fibro dT platform offers a high-capacity solution for mRNA purification with chromatography cycle times under 15 minutes. 

• Sustainable performance, with recovery over 80 percent for many chromatography cycles and across different units. 

• Helps prevent the loss of RNA molecule waste and conserves raw materials. 

Cytiva, a Danaher company and leader in the life sciences industry, has launched its fibro dT platform, for mRNA capture and purification processes. Fibro is a specially-designed material made from electrospun cellulose that helps capture and purify RNA. It’s made to a consistent quality standard, which helps reduce the loss of valuable RNA. Because of its unique structure and design, it can handle large amounts of RNA efficiently and speeds the purification process by avoiding the need for the RNA to move into tiny resin beads. 

Emmanuel Abate, President of Genomic Medicine at Cytiva, says: “The industry has long sought efficient methods to capture valuable molecules, minimizing waste and maximizing yield. Fibro dT achieves this quickly and cost-effectively, ultimately benefitting patients in need of advanced therapies.” 

Cytiva has worked with its fellow Danaher affiliate company, Aldevron, on early versions of this technology to learn more quickly what customers want. Mark Wetzel, VP and General Manager of mRNA Services, Aldevron, says: “By combining Cytiva’s dT20 fiber adsorber and our end-to-end mRNA production, we’re streamlining the journey from research to clinic. Together, we’re raising the bar for flexibility, speed, and reliability in mRNA purification and manufacturing.” 

Key Features 

• 6 mg/mL mRNA binding capacity (typical 2000‑mer with poly(A) tail) 

• < 15 minutes per chromatography cycle (0.4 mL unit) 

• High reproducibility across cycles and batches 

• Engineered for lower‑salt loading, helping limit precipitation risk and improve impurity clearance 

• ÄKTA™‑compatible workflows for streamlined setup and training 

Product Information: Cytiva™ fibro dT | Cytiva